Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

(2012) Antje Krohn et al.   AMERICAN JOURNAL OF PATHOLOGY

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

(2012) J Cuzick et al.   BRITISH JOURNAL OF CANCER

An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy

(2012) Emmanuel S. Antonarakis et al.   CANCER

Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer

(2012) Alison H M Reid et al.   MODERN PATHOLOGY

PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

(2011) T. L. Lotan et al.   CLINICAL CANCER RESEARCH

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study

(2011) Jack Cuzick et al.   LANCET ONCOLOGY

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression

(2011) Zhihu Ding et al.   NATURE

Molecular classification of prostate cancer using curated expression signatures

(2011) E. K. Markert et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

(2010) A H M Reid et al.   BRITISH JOURNAL OF CANCER

An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent

(2010) Ramzi Rajab et al.   MODERN PATHOLOGY

Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort

(2010) Ramzi Rajab et al.   VIRCHOWS ARCHIV

A Robust Immunohistochemical Assay for Detecting PTEN Expression in Human Tumors

(2010) Zaina Sangale et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer

(2009) Sak Kudahetti et al.   BJU INTERNATIONAL

Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement

(2009) C S Foster et al.   BRITISH JOURNAL OF CANCER

Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study

(2009) D M Berney et al.   BRITISH JOURNAL OF CANCER

Is PTEN loss associated with clinical outcome measures in human prostate cancer?

(2008) P McCall et al.   BRITISH JOURNAL OF CANCER